Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
When is the SARS-CoV-2 infection over and what is post-COVID?

Josef Finsterer

PII: S2049-0801(22)00310-7
DOI: https://doi.org/10.1016/j.amsu.2022.103550
Reference: AMSU 103550

To appear in: Annals of Medicine and Surgery

Received Date: 16 March 2022
Accepted Date: 26 March 2022

Please cite this article as: Finsterer J, When is the SARS-CoV-2 infection over and what is post-COVID?, Annals of Medicine and Surgery (2022), doi: https://doi.org/10.1016/j.amsu.2022.103550.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd.
When is the SARS-CoV-2 infection over and what is post-COVID?

Short title: Post-COVID neurology

Josef Finsterer, MD, PhD [1],

[1] Neurology & Neurophysiology Center, Vienna, Austria, ORCID: 0000-0003-2839-7305, Tel. 0043-1-5861075,

Number of authors: 1
Number of words (abstract): 0
Number of words (body): 508
Number of references: 5
Number of tables: 0
Number of figures: 0

Key words: Leigh syndrome, mtDNA, mitochondrial epilepsy, lactic acidosis, pancreatitis

Corresponding author:
Finsterer J, MD, PhD
Postfach 20
1180 Vienna, Austria
Tel. +43-1-5861075
Fax. +43-1-5861075
E-mail: fipaps@yahoo.de
When is the SARS-CoV-2 infection over and what is post-COVID?

Short title: Post-COVID neurology

Number of authors: 1
Number of words (abstract): 0
Number of words (body): 508
Number of references: 5
Number of tables: 0
Number of figures: 0

Key words: Leigh syndrome, mtDNA, mitochondrial epilepsy, lactic acidosis, pancreatitis

Corresponding author:
Letter to the Editor
We read with interest the article by Ahmed et al. about a meta-analysis of the neurological complications of COVID-19 patients [1]. Only studies in which neurological compromise developed after the PCR for SARS-CoV-2 became negative or studies of patients who had recovered from COVID-19 and who developed neurological disease after full recovery were included [1]. It was concluded that despite recovery from the acute infection, there may be persistent illness that requires extensive follow-up of COVID-19 patients, including those initially thought to be asymptomatic [1]. The study is appealing but raises concerns that need to be discussed.
A limitation of the study is that the inclusion criteria were based on a negative PCR for SARS-CoV-2 or the end of clinical manifestations of COVID-19 [1]. Material for PCR tests is usually taken from naso-pharyngeal swabs. However, a negative PCR test does not rule out that a patient is still infected with the virus. Although the respiratory tract is the main site of infection, there are a number of extra-pulmonary manifestations of SARS-CoV-2 infections, even at onset of the infection [2]. In addition, recovery from lung disease does not mean that the infection is over. The immune response against the virus continues even after the lung symptoms have subsided. Since many manifestations of COVID-19 are due to the immune response against the virus, considering the end of pulmonary manifestations as the end of the disease is not justified. For example, the case reported by Ishaq et al. and included in table 1, developed opsoclonus myoclonus two days after recovery from the pulmonary infection [3]. Thus, opsoclonus is not really a post-infectious phenomenon but pathophysiologically linked to the infection. The same applies to venous sinus thrombosis (VST), which occurs not only as a post-vaccination phenomenon, but also during a SARS-CoV-2 infection [4]. VST can be due to immune thrombocytopenia (ITP), which can develop as early as the pulmonary phase. However, VST may develop not earlier than after the patient had become PCR negative.
According to table 1 there are 12 patients in whom the latency period between the COVID-19 infection and the onset of neurological disease exceeded 30 days [1]. The longest latency of the 60 included patients was even 130 days [1]. Given these numbers, it is quite unlikely that there is a causal relation between the SARS-CoV-2 infection and the neurological compromise. These 12 patients in particular should be investigated for alternative causes of the neurological disease. Guillain-Bare syndrome (GBS) usually develops within four weeks after onset of the SARS-CoV-2 infection [5].
Another limitation of the study is that the spectrum of neurological disease after recovery from COVID-19 is broader than shown in the index study. It also includes conditions such as ventriculitis, hypophysitis, cerebrellitis, brainstem encephalitis, cerebral vasculitis, or venous sinus thrombosis.

Overall, the interesting study has some limitations and inconsistencies that call their results and their interpretation into question. Addressing these issues would strengthen the conclusions and could improve the status of the study. We disagree with the notion that a negative PCR test or absence of pulmonary symptoms spells the end of COVID-19.
Declarations
Funding sources: no funding was received
Conflicts of interest: none
Acknowledgement: none
Ethics approval: was in accordance with ethical guidelines. The study was approved by the institutional review board
Consent to participate: was obtained from the patient
Consent for publication: was obtained from the patient
Availability of data: all data are available from the corresponding author
Code availability: not applicable
Author contribution: JF: design, literature search, discussion, first draft, critical comments, final approval, DM: literature search, discussion, critical comments, final approval
References

1 Ahmed JO, Ahmed SA, Hassan MN, Kakamad FH, Salih RQ, Abdulla BA, Rahim Fattah FH, Mohammed SH, Ali RK, Salih AM. Post COVID-19 neurological complications; a meta-analysis. Ann Med Surg (Lond). 2022 Mar 3:103440. doi: 10.1016/j.amsu.2022.103440.

2 Finsterer J, Scorza FA, Scorza CA, Fiorini AC. Extrapulmonary onset manifestations of COVID-19. Clinics (Sao Paulo). 2021 Jul 5;76:e2900. doi: 10.6061/clinics/2021/e2900.

3 Ishaq H, Durrani T, Umar Z, Khan N, McCombe P, Ul Haq MA. Post-COVID Opsoclonus Myoclonus Syndrome: A Case Report From Pakistan. Front Neurol. 2021 Jun 7;12:672524. doi: 10.3389/fneur.2021.672524.

4 Bahadorizadeh L, Emamikhah M, Pour Mohammad A, Gholizadeh Mesgarha M. Simultaneous Occurrence of Cerebral Venous Sinus Thrombosis and Immune Thrombocytopenic Purpura in a Patient with a History of COVID-19 Infection. Neurol Ther. 2022 Mar;11(1):491-497. doi: 10.1007/s40120-021-00294-9.

5 Finsterer J, Scorza FA. Guillain-Barre syndrome in 220 patients with COVID-19. Egypt J Neurol Psychiatr Neurosurg. 2021;57(1):55. doi: 10.1186/s41983-021-00310-7.
The following information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories then this should be stated.

Please state any conflicts of interest
All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

none

Please state any sources of funding for your research
All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.

None received

Ethical Approval
Research studies involving patients require ethical approval. Please state whether approval has been given, name the relevant ethics committee and the state the reference number for their judgement.

Not applicable
Studies on patients or volunteers require ethics committee approval and fully informed written consent which should be documented in the paper.

Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request".

Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions.

Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.

Not applicable

Author contribution

Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways should be listed as contributors.

JF was responsible for all duties
Registration of Research Studies

In accordance with the Declaration of Helsinki 2013, all research involving human participants has to be registered in a publicly accessible database. Please enter the name of the registry and the unique identifying number (UIN) of your study.

You can register any type of research at http://www.researchregistry.com to obtain your UIN if you have not already registered. This is mandatory for human studies only. Trials and certain observational research can also be registered elsewhere such as: ClinicalTrials.gov or ISRCTN or numerous other registries.

1. Name of the registry:

2. Unique Identifying number or registration ID:

3. Hyperlink to your specific registration (must be publicly accessible and will be checked):

Guarantor

The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish